It’s a busy time in the healthcare world, and keeping up with all the changes can feel like a lot. From how we invest in new tech to how doctors and patients connect, things are shifting. Plus, there are new rules and big companies making moves. This article, inspired by the insights from healthcare dive, breaks down some of the biggest trends shaping healthcare right now. Let’s take a look at what’s happening.
Key Takeaways
- Big money is going into a few large deals in digital health, meaning not all startups are getting funded equally.
- Artificial intelligence is becoming a standard part of many healthcare companies, making it hard to track as a separate category.
- Telehealth use in regular doctor visits has settled down, and health systems are still figuring out if it’s worth the investment.
- Major companies like Teladoc, UHS, and Amazon are making strategic moves through acquisitions and restructuring their healthcare efforts.
- New laws are being discussed that could affect things like drug pricing programs, Medicaid, AI use, and how hospitals are paid.
Digital Health Investment Trends
Okay, so let’s talk about where the money is going in digital health. It’s been a bit of a mixed bag lately. On one hand, the total amount of cash being invested in the first quarter of 2026 actually went up compared to last year. We saw about $4 billion flow into companies, which is more than the $3 billion from the same time in 2025. But here’s the catch: that money isn’t spread out evenly.
Concentration of Funds in Mega-Deals
It seems like a big chunk of that investment is going into just a few really large deals. We’re talking about "mega-deals," which are rounds of funding over $100 million. In fact, almost 60% of all the money invested in the first quarter went into just a dozen of these massive rounds. This means fewer companies are getting the bulk of the funding, making it a pretty selective market right now.
Rise in Average Deal Size
Because of these big deals, the average amount of money a company is raising in a single round has also gone up. In the first quarter of 2026, the average deal size hit $36.7 million. That’s the highest we’ve seen since 2021. Last year, the average was closer to $29.3 million. So, while there are fewer deals overall getting the big money, the ones that do are getting a lot more cash.
Here’s a quick look at how the funding has been shaping up:
| Quarter | Total Investment | Number of Deals | Average Deal Size |
|---|---|---|---|
| Q1 2025 | $3 billion | 122 | $29.3 million |
| Q1 2026 | $4 billion | 110 | $36.7 million |
The ‘Haves and Have-Nots’ Funding Landscape
This trend really highlights a "haves and have-nots" situation in digital health funding. Some companies are managing to snag these huge investment rounds, while others are finding it much harder to get any funding at all. It’s not just about having a good idea anymore; it seems like you need to be in the right place at the right time with a proven track record to attract significant capital. This selective environment means startups really need to stand out to get noticed by investors.
Artificial Intelligence in Healthcare
Growing Interest and Investment
It’s pretty clear that artificial intelligence is a hot topic in healthcare right now. We’re seeing a lot more money flowing into companies that are building AI tools for the medical field. Last year, a significant chunk of all the funding for digital health companies went to those that specifically mentioned AI in their offerings. That’s a big jump from just a couple of years ago.
AI as a Core Focus for Startups
This surge in interest means that many new companies are making AI a central part of what they do. They’re not just adding a little AI feature; it’s often the main reason they exist. This is changing how we think about digital health startups.
Blurring Distinction of ‘AI Deals’
Because AI is becoming so common, it’s getting harder to label certain funding rounds as purely ‘AI deals.’ It used to be easier to track, but now, AI is becoming a standard part of how digital health companies are built and how they operate. It’s almost like a basic requirement, not a special feature anymore. This makes it tricky to pinpoint exactly how much investment is just for AI versus other digital health innovations that happen to use AI.
Telehealth Evolution and Adoption
It feels like just yesterday that telehealth exploded onto the scene, and now things are starting to settle down a bit. For primary care, the numbers show that telehealth visits have pretty much leveled off. We’re seeing it hold steady at around 6% to 7% of all visits, which suggests we’ve found a kind of new normal between virtual and in-person appointments. It’s not the wild west of virtual care anymore; it’s become a more integrated part of how people get routine care.
But here’s the kicker: not everyone is seeing the financial upside. A recent survey found that fewer than 30% of health system leaders reported getting a significant return on investment from their virtual care setups. That’s a pretty low number, and it makes you wonder about the long-term sustainability for some providers. It’s one thing to offer virtual visits, but it’s another to make them financially work.
Stabilization of Telehealth Use in Primary Care
As mentioned, the big story here is stability. After the initial surge, telehealth in primary care has found its footing. It’s not the go-to for everything, but it’s definitely here to stay for certain types of appointments. Think follow-ups, prescription refills, or discussing test results – those kinds of things are well-suited for a virtual visit.
Health Systems’ ROI on Virtual Care
This is where things get a bit murky. While patients might like the convenience, health systems are struggling to see the financial benefits. The low ROI reported by leaders points to challenges in:
- Reimbursement rates: Are they getting paid enough for virtual visits compared to in-person ones?
- Technology costs: Setting up and maintaining the right platforms isn’t cheap.
- Patient adoption: Getting everyone comfortable and able to use the technology can be a hurdle.
International Expansion in Virtual Care
While some are grappling with ROI at home, others are looking abroad. We’re seeing telehealth companies actively pursuing international markets. This is often part of a larger strategy to grow their reach and find new revenue streams. It’s a way to diversify and tap into markets where virtual care might be less saturated or where there’s a clear need for accessible healthcare solutions.
Mergers, Acquisitions, and Market Strategy
Big companies are making moves in the healthcare space, buying up smaller ones or changing how they operate. It’s a bit of a reshuffle, and it tells us a lot about where things are headed.
Teladoc’s M&A Strategy
Teladoc, a big name in telehealth, has been busy acquiring other companies. They picked up Catapult Health, which focuses on preventive care, and UpLift, a mental health provider. This shows they’re trying to build out a more complete set of services. It seems like they want to be a one-stop shop for virtual health needs.
UHS Acquires Talkspace for Behavioral Health Growth
Universal Health Services (UHS) made a significant move by acquiring Talkspace. This acquisition is all about boosting their presence in behavioral health. With mental health becoming more of a focus, UHS is positioning itself to offer more support in this area.
Amazon Restructures Healthcare Business
Amazon is also shaking things up. They’ve been making changes to their healthcare business. While the exact details are still unfolding, it looks like they’re trying to find a more effective way to compete and grow in this complex market. It’s a sign that even tech giants are figuring out their place in healthcare.
Navigating Healthcare Legislation
Lawmakers are busy this year, tossing around a bunch of new bills that could really shake things up in healthcare. It feels like every few months, there’s a new proposal or a change to an old one.
Key Bills Targeting Core Healthcare Issues
There’s a lot on the table right now. Congress is looking at everything from how drug prices are set to how hospitals get paid, especially those that serve a lot of low-income patients.
- The 340B Drug Pricing Program: This program helps certain hospitals and clinics buy outpatient drugs at a reduced price. There’s ongoing debate about how it’s being used and whether it’s achieving its goals. Some groups want to see changes to how discounts are applied.
- Medicaid Expansion and Funding: Discussions continue around expanding Medicaid coverage to more people and how to fund the program long-term. This impacts millions of Americans and the providers who care for them.
- Artificial Intelligence in Healthcare: With AI becoming more common, lawmakers are starting to consider rules around its use. This includes patient privacy, data security, and making sure AI tools are safe and effective.
Legislation on 340B, Medicaid, and AI
These specific areas are getting a lot of attention. For 340B, there’s a push to clarify rules and prevent what some see as abuses of the system. On the Medicaid front, states are still figuring out the best ways to manage their programs and cover their residents. And for AI, the focus is on responsible development and deployment, trying to get ahead of potential problems before they become widespread.
Site-Neutral Payment Proposals
Another big topic is site-neutral payments. The idea here is to pay the same rate for the same service, regardless of whether it’s provided in a hospital or a doctor’s office. Proponents say this could lower costs for patients and the system overall. However, hospitals, especially those in rural areas or with large charity care loads, worry it could hurt their finances. It’s a complex issue with strong opinions on both sides. The outcome of these legislative efforts will likely shape how healthcare providers operate and how patients access care for years to come.
The Digital Health IPO Landscape
Narrow Window for Public Offerings
Going public used to be a big goal for many digital health companies, especially after the rush in 2021. But lately, the door to the stock market has been pretty tight. It feels like only a few companies have managed to make it through. We saw a bit of a thaw last year when a couple of companies, Hinge Health and Omada Health, actually went public. That gave some hope, but it’s still not exactly a wide-open highway.
Impact of Policy and Economic Uncertainty
Deciding when to go public is a real head-scratcher right now. There’s a lot of back and forth with policies and the economy, and that makes it tough for companies to know the right time. When you go public, there are expectations to meet, and you have to hit the ground running. If the market is shaky or policies are changing, it adds a whole layer of stress to that.
Volatile Capital Markets and Exit Timing
Honestly, the stock market has been a bit of a rollercoaster lately. Things like inflation and global events have made it unpredictable. This makes it really hard to guess when the best time might be to sell shares or for investors to get their money back. You hear whispers about companies getting ready, but many are still just waiting for a clearer sign. It’s a waiting game for sure.
Wrapping It Up
So, what does all this mean for the healthcare world? It’s a lot, right? We’ve seen how digital health funding is getting serious, with big money going to fewer companies, and AI is basically everywhere now, changing how things are built. Plus, telehealth is finding its footing, and big players like Amazon and Teladoc are making moves, sometimes buying up other companies. It feels like things are shifting, and keeping up with all these changes is definitely a full-time job. It’s going to be interesting to see how all these pieces fit together in the coming months and years.
